0000000000214414

AUTHOR

Winfried V. Kern

showing 2 related works from this author

Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors

2003

Morbidity and mortality in patients with malignancies, especially leukemia and lymphoma, are increased by invasive fungal infections. Since diagnosis of invasive fungal infection is often delayed, antifungal prophylaxis is an attractive approach for patients expecting prolonged neutropenia. Antifungal prophylaxis has obviously attracted much interest resulting in dozens of clinical trials since the late 1970s. The non-absorbable polyenes are probably ineffective in preventing invasive fungal infections, but may reduce superficial mycoses. Intravenous amphotericin B and the newer azoles were used in clinical trials, but their role in antifungal prophylaxis is still not well defined. Allogene…

0303 health sciencesmedicine.medical_specialty030306 microbiologybusiness.industryOpportunistic infectionItraconazoleHematologyGeneral MedicineNeutropeniamedicine.disease3. Good healthClinical trial03 medical and health sciences0302 clinical medicineAmphotericin BChemoprophylaxisImmunologyMedicine030212 general & internal medicinebusinessIntensive care medicineMycosisFluconazolemedicine.drugAnnals of Hematology
researchProduct

Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of …

2006

Morbidity and mortality in patients with malignancies are increased by viral infections. These mostly are reactivations of asymptomatic latent infections. They primarily concern clinical entities associated with the reactivation of herpes viruses, such as varicella zoster virus (VZV) and cytomegalovirus (CMV). Respiratory tract infections caused by influenza, parainfluenza or respiratory syncytial virus (RSV) are less common. Since reactivation of latent infections has major clinical impact, antiviral prophylaxis is an attractive approach for patients expecting immunosuppression. The main risk factor for clinically relevant reactivation is profound disruption of cellular immune response. Du…

virusesmedicine.medical_treatmentCongenital cytomegalovirus infectionAntineoplastic AgentsNeutropeniamedicine.disease_causeAntiviral AgentsVirusHerpesviridae03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansRespiratory tract infectionsbusiness.industryVaricella zoster virusvirus diseasesImmunosuppressionHematologymedicine.disease3. Good healthOncologyVirus Diseases030220 oncology & carcinogenesisImmunologyAlemtuzumabbusinessImmunosuppressive Agents030215 immunologymedicine.drugStem Cell TransplantationAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct